Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 768470, 10 pages
http://dx.doi.org/10.1155/2015/768470
Research Article

Correlation between Genetic Variations and Serum Level of Interleukin 28B with Virus Genotypes and Disease Progression in Chronic Hepatitis C Virus Infection

1Department of Infection and Immunity, Research Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
2Liver Disease Research Center, King Saud University, Riyadh, Saudi Arabia
3Section of Gastroenterology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
4Gastroenterology Unit, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia
5Gastroenterology Unit, Department of Medicine, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
6Department of Gastroenterology, Prince Sultan Medical Military City, Riyadh, Saudi Arabia

Received 26 August 2014; Revised 8 January 2015; Accepted 9 January 2015

Academic Editor: Mario Clerici

Copyright © 2015 Ahmed Al-Qahtani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Lavanchy, “The global burden of hepatitis C,” Liver International, vol. 29, no. 1, pp. 74–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Barrera, M. Bruguera, M. Guadalupe Ercilla et al., “Persistent Hepatitis C viremia after acute self-limiting posttransfusion Hepatitis C,” Hepatology, vol. 21, no. 3, pp. 639–644, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. L. B. Seeff, “Natural history of chronic hepatitis C,” Hepatology, vol. 36, no. 5, supplement 1, pp. S35–S46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., “Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. J. G. McHutchison, E. J. Lawitz, M. L. Shiffman et al., “Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection,” The New England Journal of Medicine, vol. 361, no. 6, pp. 580–593, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Kohli, A. Shaffer, A. Sherman, and S. Kottilil, “Treatment of hepatitis C: a systematic review,” The Journal of the American Medical Association, vol. 312, no. 6, pp. 631–640, 2014. View at Publisher · View at Google Scholar
  8. D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Suppiah, M. Moldovan, G. Ahlenstiel et al., “IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy,” Nature Genetics, vol. 41, no. 10, pp. 1100–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. L. Thomas, C. L. Thio, M. P. Martin et al., “Genetic variation in IL28B and spontaneous clearance of hepatitis C virus,” Nature, vol. 461, no. 7265, pp. 798–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. V. Kotenko, G. Gallagher, V. V. Baurin et al., “IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex,” Nature Immunology, vol. 4, no. 1, pp. 69–77, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Sheppard, W. Kindsvogel, W. Xu et al., “IL-28, IL-29 and their class II cytokine receptor IL-28R,” Nature Immunology, vol. 4, no. 1, pp. 63–68, 2003. View at Publisher · View at Google Scholar
  14. T. Marcello, A. Grakoui, G. Barba-Spaeth et al., “Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics,” Gastroenterology, vol. 131, no. 6, pp. 1887–1898, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. D. Robek, B. S. Boyd, and F. V. Chisari, “Lambda interferon inhibits hepatitis B and C virus replication,” Journal of Virology, vol. 79, no. 6, pp. 3851–3854, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Langhans, B. Kupfer, I. Braunschweiger et al., “Interferon-lambda serum levels in hepatitis C,” Journal of Hepatology, vol. 54, no. 5, pp. 859–865, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Bruix, M. Sherman, J. M. Llovet et al., “Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver,” Journal of Hepatology, vol. 35, no. 3, pp. 421–430, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. A. A. Al-Qahtani, S. Rubino, and M. N. Al-Ahdal, “Sequence variation of the HVR1 region of hepatitis C virus in response to interferon-alpha and ribavirin treatment,” Journal of Infection in Developing Countries, vol. 5, no. 5, pp. 370–376, 2011. View at Google Scholar · View at Scopus
  19. D. G. Murphy, B. Willems, M. Deschênes, N. Hilzenrat, R. Mousseau, and S. Sabbah, “Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences,” Journal of Clinical Microbiology, vol. 45, no. 4, pp. 1102–1112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Kelly, P. Klenerman, and E. Barnes, “Interferon lambdas: the next cytokine storm,” Gut, vol. 60, no. 9, pp. 1284–1293, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Abe, C. N. Hayes, H. Ochi et al., “IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy,” Journal of Hepatology, vol. 54, no. 6, pp. 1094–1101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Ank, H. West, C. Bartholdy, K. Eriksson, A. R. Thomsen, and S. R. Paludan, “Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo,” Journal of Virology, vol. 80, no. 9, pp. 4501–4509, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Sirén, J. Pirhonen, I. Julkunen, and S. Matikainen, “IFN-α regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29,” Journal of Immunology, vol. 174, no. 4, pp. 1932–1937, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Abe, H. Ochi, T. Maekawa et al., “Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients,” Journal of Hepatology, vol. 53, no. 3, pp. 439–443, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. P.-Y. Bochud, S. Bibert, Z. Kutalik et al., “IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes,” Hepatology, vol. 55, no. 2, pp. 384–394, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Fabris, E. Falleti, A. Cussigh et al., “IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC,” Journal of Hepatology, vol. 54, no. 4, pp. 716–722, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Eurich, S. Boas-Knoop, M. Bahra et al., “Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy,” Transplantation, vol. 93, no. 6, pp. 644–649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Joshita, T. Umemura, Y. Katsuyama et al., “Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection,” Human Immunology, vol. 73, no. 3, pp. 298–300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Akbar, M. Idrees, S. Butt et al., “High baseline interleukine-8 level is an Independent risk factor for the achievement of sustained virological response in chronic HCV patients,” Infection, Genetics and Evolution, vol. 11, no. 6, pp. 1301–1305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Zhang, L. Miao, F. Han, and X.-G. Dou, “Cytokine levels in serum of patients with chronic hepatitis C and its significance,” Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, vol. 27, no. 3, pp. 301–303, 2011. View at Google Scholar · View at Scopus